News
SMC approval welcome news for breast cancer patients
The SMC has accepted Trodelvy (sacituzumab govitecan) for use in Scotland on the NHS, for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).